H eparin-induced thrombocytopenia (HIT) is an adverse drug reaction characterized by thrombocytopenia and a high risk for venous or arterial thrombosis. 1 It is caused by heparin-dependent, plateletactivating antibodies that recognize a "self" protein, platelet factor 4 (PF4), bound to heparin. The resulting platelet activation is associated with increased thrombin generation ( Figure) . 2 Typically, the platelet count fall begins 5 to 10 days after starting heparin, although a rapid platelet count fall can occur in a patient who has antibodies from recent heparin use. 3 Remarkably, transience of HIT antibodies permits safe heparin reexposure in selected patients (for example, heart surgery patients) despite a history of HIT. 3, 4 
Case Summary
A 61-year-old woman 5 with Raynaud's phenomenon underwent mechanical aortic valve replacement for aortic insufficiency. She developed persistent vasospasm of fingers and toes after surgery that responded to warming measures. Unfractionated heparin (UFH) prophylaxis was given until postoperative day 4, and warfarin (5, 5, and 2.5 mg) was given from days 2 to 4. On day 8, the patient developed ischemic necrosis of multiple fingers and toes. The platelet count had fallen by 44% from 221ϫ10 9 /L (day 4) to 124ϫ10 9 /L (day 8), and the international normalized ratio (INR) rose to 4.3. The diagnosis of delayed-onset HIT complicated by warfarin-induced digital necrosis was supported by strong positive tests for HIT antibodies, including a positive platelet serotonin release assay (100% serotonin release; normal Ͻ20%).
When Should HIT Be Suspected?
Thrombocytopenia is common in hospitalized patients receiving UFH, yet only a minority have HIT. A clinical scoring system may be useful for identifying those with HIT.
Pretest Probability of HIT:
The "4 T's" Table 1 summarizes a clinical scoring system ("4 T's") for estimating the pretest probability of HIT 1 based on its characteristic features (Thrombocytopenia, Timing, Thrombosis) and the absence of oTher explanation(s). Preliminary evaluation suggests that HIT antibodies are unlikely (Ͻ5%) when a low score (Յ3) is obtained but are likely (Ͼ80%) with a high score (Ն6). An intermediate score (4 or 5) indicates a clinical profile compatible with HIT but with another plausible explanation. Laboratory testing for HIT antibodies is especially useful in this last group of patients.
HIT After Cardiac Surgery
HIT often begins 5 to 10 days after cardiac surgery, especially if UFH is given after postoperative day 4. 6 It is recommended that the platelet count be monitored at least every other day in these patients. 4, 6 Thrombosis beginning on or after postoperative day 5 is suspicious for HIT and should prompt platelet count evaluation.
In contrast, HIT within the first 4 days after cardiac surgery is uncommon even in patients who received heparin before surgery. This is because heparin-induced immunization in preoperative medical settings is relatively uncommon and because thrombocytopenia soon after cardiac surgery invariably can be explained by hemodilution and platelet consumption. 4 Delayed-Onset HIT Sometimes, the platelet count begins to fall in HIT only after heparin has been stopped. Such patients with delayed-onset HIT can present as inpatients or outpatients and typically have strong positive HIT antibody tests caused by high titers of antibodies with autoimmune features, such as platelet activation in the absence of heparin. 7 
HIT and Invasive Cardiology
Thrombocytopenia is relatively common after percutaneous coronary intervention (PCI). However, abrupt onset of severe thrombocytopenia within hours of PCI utilizing UFH and a platelet glycoprotein (GP) IIb/IIIa (fibrinogen receptor) antagonist (abciximab, eptifibatide, tirofiban) almost always is caused by the GP IIb/IIIa antagonist because of naturally occurring antibodies that react against GP IIb/IIIa in the presence of the drug. 8 If HIT is wrongly diagnosed in such a patient and the patient is anticoagulated, severe bleeding could result.
HIT and Clinical Cardiology
Cardiologists prescribe UFH for many clinical situations, including acute coronary syndrome, congestive heart failure, and atrial fibrillation, which creates the potential for HIT. Even low-dose subcutaneous UFH has been reported to cause HIT in about 1% of such patients. 9 Lowmolecular-weight heparin (LMWH) probably reduces risk of HIT in these patients (although this remains un- 1, 6 At our center, where we use the platelet serotonin release assay (a washed platelet activation assay), we have observed that most patients with HIT have a strong positive test result (Ͼ80% serotonin release), which yields good diagnostic specificity. Delays in obtaining test results mean that physicians must make appropriate decisions on the basis of their assessment of the pretest probability of HIT.
Treatment of HIT
The box summarizes key treatment principles. 2 In patients strongly suspected of having HIT, the physician should replace heparin with an appropriate nonheparin anticoagulant. In the United States, two direct thrombin inhibitors (DTIs), lepirudin and argatroban, are approved for treating thrombosis complicating HIT. In some jurisdictions (but not the United States), danaparoid (a mixture of nonheparin anticoagulant glycosaminoglycans with predominant anti-factor Xa activity) is approved and available. Other marketed anticoagulants that have shown favorable results in HIT and may be appropriate "off-label" treatments include bivalirudin and fondaparinux, although experience with these drugs in HIT is limited. 4 If HIT is strongly suspected, all heparin should be stopped and further heparin avoided. UFH is commonly used to "flush" intravascular catheters, and an order simply to "discontinue heparin" may not necessarily prevent such incidental heparin exposure.
Warfarin predisposes to microvascular thrombosis in patients with acute HIT, for example, warfarin-induced venous limb gangrene 11 and skin necrosis 12 syndromes. Affected patients typically have a supratherapeutic INR (typically Ͼ4.0) that corresponds to severe protein C depletion. It is recommended that warfarin not be started until substantial resolution of thrombocytopenia has occurred (preferably, platelet count Ͼ150ϫ10 9 /L). 4 Reversal of warfarin anticoagulation with vitamin K is advised when HIT is diagnosed only after warfarin has already been started 4 ; besides reducing risk of coumarin necrosis, it minimizes risk of DTI underdosing (because warfarin prolongs the activated partial thromboplastin time [aPTT] used to monitor the DTI).
Lepirudin
Lepirudin is a recombinant hirudin (leech anticoagulant) that forms irreversible 1:1 complexes with thrombin. Its half-life (80 minutes) increases dramatically in renal insufficiency. Because no antidote exists, it must be used cautiously or avoided completely in patients with renal compromise. The approved dose is 0.4 mg/kg (IV bolus) followed by an initial infusion rate at In general, the greater the magnitude of a positive test result, the greater the likelihood that the patient has HIT, eg, most patients with HIT have serotonin release Ͼ80% and optical density Ͼ1.0 absorbance unit, ie, values well above the cutoffs defining a positive test.
*Assay from GTI (Brookfield, Wis) uses PF4/polyvinyl sulfonate, whereas assay from Stago (Asnieres, France) uses PF4/heparin. †High sensitivity for clinical HIT (similar to EIAs) but with greater diagnostic specificity than the EIAs. 
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